Tebapivat is under clinical development by Agios Pharmaceuticals and currently in Phase I for Sickle Cell Disease.

Time for some extremely good news: the cures for catastrophic diseases like cancer, Parkinson’s, heart disease and HIV are ...

A once-groundbreaking sickle cell disease drug — at the center of a $5.4 billion acquisition two years ago — is the subject ...

The sister of a"caring and selfless” dad whose life was tragically cut short of Christmas Day after a long battle with sickle ...

This phase 1–2, randomised, double-blind, placebo-controlled trial enrolled 130 patients aged 18 or older with confirmed ...

From reprogrammed stem cells to next-generation gene editing, 2024 has seen some incredible developments with the potential ...

Historically, sickle cell anaemia has been widely neglected within its global epicentre of sub-Saharan Africa. More than ...

Strategies to reduce disease burden in alpha- or beta-thalassemia, sickle cell disease, and polycythemia vera, and insights into anemia in IBD, are among anemia highlights from ASH 2024.